Fig. 6
From: The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer
TLR4 inhibition hampers PTX3 tumorigenic activity in TNBC. (A) Left panel: inhibition of MDA-MB-231 shNT and shPTX3 cell proliferation after treatment with increasing doses of TAK-242. Right panel: colony formation assay of MDA-MB-231 shNT and shPTX3 cells treated or not with TAK-242. (B) Tumor growth and weight of MDA-MB-231 shNT (left panel) and shPTX3 (right panel) orthotopic tumors implanted into immune-compromised mice and treated or not with 3 mg/Kg TAK-242. Blue arrows indicate the days of treatment. n = 8/10 mice/group. (C) Immunohistochemical analysis of MDA-MB-231 shNT (left panel) and shPTX3 (right panel) tumors treated or not with 3 mg/Kg TAK-242 (same tumors shown in B). Scale bar: 50 μm. (D) Western blot analysis of MDA-MB-231 shNT cells treated or not with 10 or 20 µM of TAK-242. (E) Immunohistochemical analysis for PTX3 expression of MDA-MB-231 shNT tumors treated or not with 3 mg/Kg TAK-242 (same tumors shown in B). Scale bar: 50 μm
Data are the mean ± SEM, experiments were performed in triplicate. In box and whiskers graphs, boxes extend from the 25th to the 75th percentiles, lines indicate the median values, and whiskers indicate the range of values. n = 8/10 mice/group; ***p < 0.001